(0.34%) 5 117.13 points
(0.34%) 38 369 points
(0.40%) 15 991 points
(-0.98%) $83.03
(5.51%) $2.03
(0.33%) $2 355.00
(0.46%) $27.66
(4.06%) $959.55
(-0.26%) $0.932
(-0.42%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19...
Stats | |
---|---|
本日の出来高 | 9 704.00 |
平均出来高 | 36 316.00 |
時価総額 | 939 649 |
EPS | $0 ( 2024-03-21 ) |
次の収益日 | ( $0 ) 2024-06-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-07 | Bodmer Mark | Buy | 6 625 | Common Stock |
2023-11-08 | Bodmer Mark | Sell | 3 163 | Common Stock |
2023-11-07 | Bodmer Mark | Sell | 6 625 | Restricted Stock Units |
2023-11-07 | Mchale Duncan | Buy | 6 500 | Common Stock |
2023-11-08 | Mchale Duncan | Sell | 3 103 | Common Stock |
INSIDER POWER |
---|
86.65 |
Last 96 transactions |
Buy: 11 679 076 | Sell: 749 652 |
Evelo Biosciences Inc 相関
10 最も負の相関 | |
---|---|
BRIV | -0.986 |
ENTF | -0.986 |
ORIA | -0.984 |
PRLH | -0.984 |
PPYA | -0.984 |
IVCP | -0.983 |
HCNE | -0.983 |
PWUP | -0.983 |
BIOS | -0.983 |
CBRG | -0.983 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Evelo Biosciences Inc 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-26.28 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-26.28 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.09 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.37 |
Financial Reports:
No articles found.
Evelo Biosciences Inc
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。